News

Keyword Search

Year

Jul 29, 2021

CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021

SEATTLE , July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. ( CTI BioPharma ) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021 , after the close of the U.S. financial markets.

Jul 26, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , July 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated

Jul 09, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , July 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated

Jun 23, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , June 23, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but

Jun 09, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but

Jun 09, 2021

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16

SEATTLE , June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:30 p.m. ET . The conference will be held in a virtual meeting format.

Jun 01, 2021

CTI BioPharma Reports First Quarter 2021 Financial Results

- NDA for Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia Accepted with Priority Review by FDA with PDUFA Target Action Date of November 30, 2021 - - Commercialization Activities on Track to Support a Potential Approval and Launch of Pacritinib in the United

Jun 01, 2021

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis

- NDA addresses unmet medical need of myelofibrosis patients with severe thrombocytopenia - PDUFA Action Date November 30, 2021 SEATTLE , June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug

May 26, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , May 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to six new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but

May 12, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , May 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Investors

News

News

–

–

–

–